Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2937-2943

  Gong, Xiao Di ^a   Wang, Jiong Yi ^a   Liu, Feng ^a   Yuan, Hai Hua ^a   Zhang, Wen Ying ^a   Guo, Yue Hui ^a   Jiang, Bin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ABCB1 gene; Cancer pain treatment; Opioids requirements; OPRM1 gene; SNP

Indexed keywords

ABCB1 PROTEIN, HUMAN; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; NARCOTIC ANALGESIC AGENT; OPRM1 PROTEIN, HUMAN;

AGED; ANALGESIA; CHINA; COMPLICATION; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETICS; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; NOCICEPTION; NUCLEOTIDE SEQUENCE; PAIN; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANALGESICS, OPIOID; BASE SEQUENCE; CHINA; FEMALE; FENTANYL; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; P-GLYCOPROTEINS; PAIN; PAIN MANAGEMENT; PAIN PERCEPTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SEQUENCE ANALYSIS, DNA;

EID: 84880383198     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2937     Document Type: Article

References (47)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-85.
2. Baldissera VD, de Mattos AA, Coral GP, et al (2012). Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol, 11, 899-906.
3. Bayerer B, Stamer U, Hoeft A, et al (2007). Genomic Variations and Transcriptional Regulation of the Human Mu-Opioid Receptor Gene. Eur J Pain, 11, 421-7.
4. Befort K, Filliol D, Decaillot FM, et al (2001). A Single Nucleotide Polymorphic Mutation in the Human Mu-Opooid Receptor Severely Impairs Receptor Signaling. J Biol Chem, 276, 3130-7.
5. Beyer A, Koch T, Schröder H, et al (2004). Effect of the A118G polymorphism on binding affinity, potency and agonistmediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem, 89, 553-60.
6. Bond C, LaForge KS, Tian M, et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A, 95, 9608-13.
7. Campa D, Gioia A, Tomei A, et al (2008). Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther, 83, 559-66.
8. Chen CJ, Chin JE, Ueda K, et al (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-9.
9. Elliott AM, Smith BH, Penny KI, et al (1999). The epidemiology of chronic pain in the community. Lancet, 354, 1248-52.
10. Fernandez Robles CR, Degnan M, Candiotti KA(2012). Pain and genetics. Curr Opin Anaesthesiol, 25, 444-9.
11. Fujita K, Ando Y, Yamamoto W, et al (2010). Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol, 65, 251-8.
12. Haerian BS, Haerian MS (2013). OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics, 14, 813-24.
13. Hamabe W, Maeda T, Fukazawa Y, et al (2006). P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav, 85, 629-36.
14. Hirota T, Ieiri I, Takane H, et al (2003). Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos, 31, 677-80
15. Hoehe MR, Köpke K, Wendel B, et al (2000). Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet, 9, 2895-908.
16. Hoffmeyer S, Burk O, von Richter O, et al (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-8.
17. Huang P, Chen C, Mague SD, et al (2012). A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J, 441, 379-86.
18. Hung CC, Chen CC, Lin CJ, et al (2008). Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics, 18, 390-402.
19. Ikeda K, Ide S, Han W, et al (2005). How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci, 26, 311-7.
20. Kasai S, Hayashida M, Sora I, et al (2008). Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol, 377, 269-81.
21. Kasai S, Ikeda K (2011). Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics, 12, 1305-20.
22. Kimchi-Sarfaty C, Oh JM, Kim IW, et al (2007). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8.
23. Klepstad P, Fladvad T, Skorpen F, et al (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain, 152, 1139-45.
24. Kosarac B, Fox AA, Collard CD (2009). Effect of genetic factors on opioid action. Curr Opin Anaesthesiol, 22, 476-82.
25. Landau R, Kern C, Columb MO, et al (2008). Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain, 139, 5-14.
26. Leschziner G, Zabaneh D, Pirmohamed M, et al (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics, 16, 439-50.
27. Li D, Zhang GL, Lou YQ, et al (2007). Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther, 32, 89-95.
28. Lloret Linares C, Hajj A, Poitou C, et al (2011). Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. Obes Surg, 21, 1257-64.
29. Lötsch J, Geisslinger G (2006). Relevance of frequent muopioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J, 6, 200-10.
30. Lötsch J, Skarke C, Wieting J, et al (2006). Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther, 79, 72-89.
31. Mealey KL (2008). Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. Vet Parasitol, 158, 215-22.
32. Oertel BG, Schmidt R, Schneider A, et al (2006). The mu-opioid receptor gene polymorphism 118A>G depletes alfentanilinduced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics, 16, 625-36.
33. Reyes-Gibby CC, Shete S, Rakvåg T, et al (2007). Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain, 130, 25-30.
34. Salama NN, Yang Z, Bui T, et al (2006). MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci, 95, 2293-308.
35. Shabalina SA, Zaykin DV, Gris P, et al (2009). Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet, 18, 1037-51.
36. Sia AT, Lim Y, Lim EC, et al (2008). A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology, 109, 520-6.
37. Sia AT, Sng BL, Lim EC, et al (2010). The influence of ATPbinding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int J Obstet Anesth, 19, 254-60.
38. Smith K, Hopp M, Mundin G, et al (2012). Low absolute bioavailability of oral naloxone in healthy subjects. J Clin Oncol, 19, 2542-54.
39. Tan EC, Lim EC, Teo YY, et al (2009). Ethnicity and OPRM variant independently predict pain perception and patientcontrolled analgesia usage for post-operative pain. Mol Pain, 5, 32.
40. Tan EC, Tan CH, Karupathivan U, et al (2003). Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport, 14, 569-72.
41. Tang K, Wong LP, Lee EJ, et al (2004). Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet, 13, 783-97.
42. Uhl GR, Sora I, Wang Z (1999). The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A, 96, 7752-55.
43. Wang D, Johnson AD, Papp AC, et al (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics, 15, 693-704.
44. Wang D, Quillan JM, Winans K, et al (2001). Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem, 276, 34624-30.
45. Wang JB, Johnson PS, Persico AM, et al (1994). Human mu opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett, 338, 217-22.
46. Zhou B, Wang J, Yan Z, et al (2012). Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. Radiology, 262, 1014-21.
47. Zhou SF, Zhou ZW, Li CG, et al (2007). Identification of drugs that interact with herbs in drug development. Drug Discov Today, 12, 664-73.